All In Biotech

Drug Trial Radar · NCT06508320

A Clinical Study to Investigate the Safety and Immunogenicity in Relation to Product Attributes of mRNA-1083 (Severe Acute Respiratory Syndrome Coronavirus 2 [SARS-CoV-2] and Influenza Vaccine)

A Phase 2, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity in Relation to the Product Attributes of mRNA-1083 (SARS-CoV-2 and Influenza) Vaccine in Adults ≥50 to <65 Years of Age

Last checked: Nov 20, 2026Latest source record: Oct 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 931 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

931

Actual

Start

Jul 15, 2024

Primary completion

Sep 25, 2025

Study completion Sep 25, 2025

Sponsor

Lead sponsor
ModernaTX, Inc.Moderna (MRNA)
Sponsor type
Industry
First posted
Jul 18, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 50 years, up to 64 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the safety, reactogenicity, and immunogenicity in relation to the product attributes of mRNA-1083 vaccine when administered as a single intramuscular (IM) injection in adults ≥50 to \<65 years of age.

Conditions

  • Influenza
  • SARS-CoV-2

Interventions

  • mRNA-1083Biological

    IM injection in a deltoid muscle.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Geometric Mean Titer (GMT) of Anti-Hemagglutinin (HA) Antibody for Seasonal Influenza A and B StrainsTime frame: Day 29
  2. Geometric Mean Titer (GMT) of Neutralizing Antibody for SARS-CoV-2Time frame: Day 29
  3. Number of Participants With Solicited Local and Systemic Adverse Reactions (ARs)Time frame: From the day of study injection through 6 subsequent days (Up to 7 days)
  4. Number of Participants With Unsolicited Adverse Events (AEs)Time frame: From the day of study injection through 27 subsequent days (Up to 28 days)
  5. Number of Participants With Medically Attended AEs (MAAEs), Adverse Events of Special Interest (AESIs), Serious Adverse Events (SAEs), and AEs Leading to Study DiscontinuationTime frame: From Day 1 to End of Study (Up to 6 Months)

Locations

17 sites in 2 countries. Site status is shown where the registry gives one.

  • Indago Research & Health Center, Inc.

    Hialeah, Florida

  • Cenexel RCA

    Hollywood, Florida

  • Suncoast Research Group, LLC DBA Flourish Research

    Miami, Florida

  • Cenexel IRA

    Decatur, Georgia

  • DM Clinical Research - River Forest

    River Forest, Illinois

  • JCCT

    Lenexa, Kansas

  • Hassman Research Institute - Berlin - CenExel - PPDS

    Marlton, New Jersey

  • DM Clinical Research - Philadelphia

    Philadelphia, Pennsylvania

  • DM Clinical Research - Cyfair Clinical Research Center - PPDS

    Houston, Texas

  • Clinical Trials of Texas, LLC DBA Flourish Research

    San Antonio, Texas

  • DM Clinical Research - Sugarland

    Sugar Land, Texas

  • DM Clinical Research - Tomball MDC

    Tomball, Texas

  • Diex Recherche Québec Inc.

    Québec, Canada

  • Centricity Research

    Toronto, Ontario, Canada

  • Centricity Research

    Toronto, Ontario, Canada

  • Centricity Research

    Pointe-Claire, Quebec, Canada

  • Diex Recherche Sherbrooke Inc.

    Sherbrooke, Quebec, Canada

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.